Formulations for eye treatments
Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.
1. A therapeutic combination for treating an eye, comprising:
a formulation of riboflavin supplemented with oxygen, hydroxypropyl methylcellulose, one or more ionic surfactants, ethylenediaminetetraacetic acid (EDTA), a citrate;
pulsed light illumination; and
a mask configured to produce a consistent oxygen concentration above a surface of the eye.
2. The therapeutic combination of claim 1 , wherein the one or more ionic surfactants comprises benzalkonium chloride.
3. The therapeutic combination of claim 1 , wherein the pulsed light is pulsed Ultra Violet A light.
4. The therapeutic combination of claim 1 , wherein the formulation further comprises one or more anesthetic agents.
5. The therapeutic combination of claim 4 , wherein the one or more anesthetic agents is selected from the group consisting of pilocarpine, proparacaine, tetracaine, and oxybuprocaine.
6. The therapeutic combination of claim 1 , wherein the formulation further comprises one or more analgesic agents.
7. The therapeutic combination of claim 6 , wherein the one or more analgesic agents is selected from the group consisting of menthol, benzyl alcohol, and phenylethyl alcohol.
8. The therapeutic combination of claim 1 , wherein the formulation further comprises one or more shear-thinning, viscosity-increasing agents.
9. The therapeutic combination of claim 8 , wherein the one or more shear- thinning, viscosity-increasing agents is selected from the group consisting of carbomer, polycarbophil, gellan gum, and carboxymethyl cellulose sodium.
10. The therapeutic combination of claim 1 , wherein the formulation further comprises one or more tonicity agents.
11. The therapeutic combination of claim 10 , wherein the one or more tonicity agents is selected from the group consisting of glycerin, propylene glycol, polyethylene glycol (PEG)-8, ethanol, benzyl alcohol, phenylethyl alcohol, and triacetin.
12. The therapeutic combination of claim 1 , wherein the mask includes an anterior side and a posterior side, the posterior side configured to be positioned proximate to the eye and the anterior side configured to be positioned distally from the eye.
13. The therapeutic combination of claim 12 , wherein the mask includes an outer wall extending at least between the anterior side and the posterior side.
14. The therapeutic combination of claim 13 , wherein the mask further comprises a transmission region configured to allow a pulsed light to be delivered to the eye.
15. The therapeutic combination of claim 14 , wherein the pulsed light is pulsed Ultra Violet A light.
16. The therapeutic combination of claim 12 , wherein the mask further comprises an oxygen delivery system.
17. The therapeutic combination of claim 16 , wherein the mask comprises a diffuser configured to deliver the oxygen above the surface of the eye.
18. The therapeutic combination of claim 17 , wherein the oxygen concentration above the surface of the eye is greater than a concentration of oxygen in ambient air.